Journal Basic Info
- Impact Factor: 0.285**
- H-Index: 6
- ISSN: 2638-4558
- DOI: 10.25107/2638-4558
Major Scope
- Molecular Biology
- Respiratory Medicine
- Tuberculosis
- Hepatology
- Traumatology
- Geriatric Medicine
- Biochemistry and Biostatistics
- Chronic Disease
Abstract
Citation: Clin Case Rep Int. 2020;4(1):1167.DOI: 10.25107/2638-4558.1167
Colchicine May not be Preventive in COVID-19 Pneumonia: Case Report
Hasan Kayabasi, Mustafa Behcet Demirbas, Ezgi Ersoy Yesil and Dede Sit
Department of Nephrology, Health Sciences University, Turkey
*Correspondance to: Hasan Kayabasi
PDF Full Text Case Report | Open Access
Abstract:
The recent outbreak of Coronavirus Disease 2019 (COVID-19) continues to evolve in many countries and pose life-threatening clinical issues to global public health. There is no vaccine or therapeutic proven options to prevent COVID-19 infection. It has been speculated that some immunomodulating drugs may have an effect on the progression of this infection. It is reasonable that colchicine may be tested in the context of COVID-19 to detect its immunomodulatory effects which may prevent acute respiratory distress syndrome. We discussed a case with COVID-19 pneumonia using colchicine successfully treated and reviewed the literature.
Keywords:
Cite the Article:
Kayabasi H, Demirbas MB, Yesil EE, Sit D. Colchicine May not be Preventive in COVID-19 Pneumonia: Case Report. Clin Case Rep Int. 2020; 4: 1167.
